
Lucid Diagnostics (LUCD) Stock Forecast & Price Target
Lucid Diagnostics (LUCD) Analyst Ratings
Bulls say
Lucid Diagnostics is set to capitalize on the growing market opportunity for early detection of esophageal cancer with their highly accurate molecular tests, EsoGuard and EsoCheck. Their progress with Medicare and potential positive coverage, as well as partnerships and strategic initiatives, position the company for growth and success. While recent financial results may have been lower than expected, Lucid plans to continue expanding their sales force and increasing awareness of their products, with support from a Buy rating and price target from Abbott Laboratories.
Bears say
Lucid Diagnostics is a commercial-stage medical diagnostics technology company that has recently seen growth momentum in commercial health plans and has successfully achieved reimbursement for its EsoGuard test. Despite a large market opportunity of approximately $2 billion, risks to achieving profitability include balance sheet/liquidity risks, delays in gaining regulatory approvals and reimbursements, and competition within the biotech/medtech industry.
This aggregate rating is based on analysts' research of Lucid Diagnostics and is not a guaranteed prediction by Public.com or investment advice.
Lucid Diagnostics (LUCD) Analyst Forecast & Price Prediction
Start investing in Lucid Diagnostics (LUCD)
Order type
Buy in
Order amount
Est. shares
0 shares